7 results match your criteria: "USA [2] Dartmouth-Hitchcock Medical Center[Affiliation]"
Response to Hao et al.
Am J Gastroenterol
December 2018
Medical University of South Carolina, Charleston, SC, USA. University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium.
Am J Gastroenterol
September 2018
Icahn School of Medicine at Mount Sinai, New York, NY, uSA. McMaster university Medical Centre, Hamilton, ON, Canada. university of Alberta, Edmonton, AB, Canada. University of California - San Diego, La Jolla, CA, uSA. Cleveland Clinic Foundation, Cleveland, OH, uSA. Mayo Clinic, Rochester, MN, uSA. indiana university, indianapolis, iN, uSA. Dartmouth-Hitchcock Medical Center, Lebanon, NH, uSA. North Shore university Hospital, Manhasset, NY, uSA. New York university, New York, NY, uSA. Takeda Pharmaceuticals uSA inc., Deerfield, iL, uSA. Montefiore Medical Center, New York, NY, uSA. Lenox Hill Hospital, New York, NY, uSA. University of Mississippi, Jackson, MS, uSA. These authors contributed equally: Neeraj Narula, Farhad Peerani.
Objectives: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment.
Methods: Retrospective review (May 2014-December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically active UC were included.
Recurrent Acute Pancreatitis Significantly Reduces Quality of Life Even in the Absence of Overt Chronic Pancreatitis.
Am J Gastroenterol
June 2018
Medical university of South Carolina, Charleston, SC, USA. University of Pittsburgh Medical Center, Pittsburgh, PA, USA. Indiana university School of Medicine, Indianapolis, IN, USA. Richmond Gastroenterology Associates, Richmond, VA, USA. university of Michigan, Ann Arbor, MI, USA. Mayo Clinic, Jacksonville, FL, USA. Saint Louis university, St. Louis, MO, USA. Johns Hopkins Medical Institutions, Baltimore, MD, USA. Virginia Commonwealth university, Richmond, VA, USA. Brigham and Women's Hospital, Boston, MA, USA. Ohio State university, Columbus, OH, USA. Aurora St. Luke's Medical Center, Milwaukee, WI, USA. Yale School of Medicine, New Haven, CT, USA. University of Chicago, Chicago, IL, USA. Digestive Health Specialists, Tupelo, MS, USA. University of Florida, Gainesville, FL, USA. University of Alabama, Birmingham, AL, USA. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA.
Objectives: The impact of recurrent acute pancreatitis (RAP) on quality of life (QOL) is unknown. We hypothesized that RAP would reduce QOL even in the absence of chronic pancreatitis (CP).
Methods: Data were pooled from three prospective, cross-sectional studies conducted across 27 U.
Management options for patients with GERD and persistent symptoms on proton pump inhibitors: recommendations from an expert panel.
Am J Gastroenterol
July 2018
Anschutz Medical Campus, University of Colorado, Aurora, CO, USA. Vanderbilt Medical Center, Nashville, TN, USA. Mayo Clinic, Scottsdale, AZ, USA. Baylor Health Care System, Dallas, TX, USA. University of North Carolina, Chapel Hill, NC, USA. University of South Florida, Tampa, FL, USA. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Mayo Clinic, Rochester, MN, USA. Weill Cornell Medical Center, New York, NY, USA. Northwestern University, Chicago, IL, USA. Washington University, St. Louis, MO, USA. California Pacific Medical Center, San Francisco, CA, USA. Metro Health Medical Center, Cleveland, OH, USA. Medical University of South Carolina, Charleston, SC, USA. University of Wisconsin, Madison, WI, USA.
Background: The aim of this study was to assess expert gastroenterologists' opinion on treatment for distinct gastroesophageal reflux disease (GERD) profiles characterized by proton pump inhibitor (PPI) unresponsive symptoms.
Methods: Fourteen esophagologists applied the RAND/UCLA Appropriateness Method to hypothetical scenarios with previously demonstrated GERD (positive pH-metry or endoscopy) and persistent symptoms despite double-dose PPI therapy undergoing pH-impedance monitoring on therapy. A priori thresholds included: esophageal acid exposure (EAE) time >6.
Hyperbaric oxygen therapy is well tolerated and effective for ulcerative colitis patients hospitalized for moderate-severe flares: a phase 2A pilot multi-center, randomized, double-blind, sham-controlled trial.
Am J Gastroenterol
October 2018
University of California at San Diego, La Jolla, CA, USA. Dartmouth Hitchcock Medical Center, Lebanon, NH, USA. Mayo Clinic, Rochester, MN, USA. University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Background: Hyperbaric oxygen therapy (HBOT) markedly increases tissue oxygen delivery. Case series suggest it may have a potential therapeutic benefit in ulcerative colitis (UC). We investigated the therapeutic potential of HBOT as an adjunct to steroids for UC flares requiring hospitalization.
View Article and Find Full Text PDFValidation of the Kinyarwanda-version Short-Form Leeds Dyspepsia Questionnaire and Short-Form Nepean Dyspepsia Index to assess dyspepsia prevalence and quality-of-life impact in Rwanda.
BMJ Open
June 2016
College of Medicine and Health Sciences, University of Rwanda, Huye, Rwanda Butare University Teaching Hospital, Huye, Rwanda.
Objectives: We aimed to develop and validate Kinyarwanda versions of Short-Form Leeds Dyspepsia Questionnaire (SF-LDQ) and Short-Form Nepean Dyspepsia Index (SF-NDI) to measure the frequency and severity of dyspepsia and associated quality-of-life impact in Rwanda.
Setting: A single, tertiary care centre in Rwanda.
Participants: 200 consecutive Kinyarwanda-speaking patients referred to endoscopy (100 patients) or medical outpatients (100 patients).
Exploding vs. imploding headache in migraine prophylaxis with Botulinum Toxin A.
Pain
December 2006
Departments of Anesthesia and Critical Care, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA Program in Neuroscience, Harvard Medical School, Boston, MA 02115, USA Associate Neurologists of Southern Connecticut, Fairfield, CT, USA Dartmouth-Hitchcock Medical Center, Hanover, NH, USA.
Migraine headache is routinely managed using medications that abort attacks as they occur. An alternative approach to migraine management is based on prophylactic medications that reduce attack frequency. One approach has been based on local intramuscular injections of Botulinum Toxin Type A (BTX-A).
View Article and Find Full Text PDF